Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL)

Best Practice & Research. Clinical Haematology
T ZenzStephan Stilgenbauer

Abstract

Many prognostic factors have been identified in chronic lymphocytic leukaemia (CLL). Based on the assessment of B cell receptor (BCR) structure and function, a subdivision into subtypes is possible (e.g., immunoglobulin heavy chain variable gene segment (IGHV) unmutated and mutated, V3-21 usage) with distinct biological and clinical characteristics. Recurrent genomic aberrations (i.e., 11q and 17p deletion) and gene mutations (i.e., TP53 and ATM) help to define biological and clinical subgroups. In addition, serum markers (e.g., thymidine kinase (TK) and beta2-microglobulin (beta2-MG)), cellular markers (e.g., CD38 and ZAP70) and clinical staging have an impact on outcome in CLL. The biological characterisation of CLL has not only led to progress in outcome prediction but also has begun to be translated into novel treatment strategies. Nonetheless, most factors associated with prognosis have not been thoroughly interrogated for their predictive value in the light of different therapeutic approaches. With a growing number of agents acting on specific biological targets and being used in different clinical situations, the future is likely to bring the identification of predictive factors in CLL.

References

Oct 28, 1998·The Journal of Clinical Investigation·F FaisN Chiorazzi
Jan 3, 2001·The New England Journal of Medicine·H DöhnerP Lichter
Oct 27, 2001·Science·M Lagos-QuintanaT Tuschl
Nov 16, 2002·Proceedings of the National Academy of Sciences of the United States of America·George Adrian CalinCarlo M Croce
May 2, 2003·The New England Journal of Medicine·Marta CrespoEmili Montserrat
Aug 22, 2003·Nucleic Acids Research·Niklas SchultzThomas Helleday
Feb 16, 2005·The Journal of Clinical Investigation·Bradley T MessmerNicholas Chiorazzi
Feb 25, 2005·The New England Journal of Medicine·Nicholas ChiorazziManlio Ferrarini
Mar 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel J SargentLaurence Collette
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aparna RavalChristoph Plass
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan FröhlingRoss L Levine
Sep 17, 2005·Proceedings of the National Academy of Sciences of the United States of America·Amelia CimminoCarlo M Croce
Jan 19, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alexander KröberStephan Stilgenbauer
Apr 18, 2006·Seminars in Oncology·Till SeilerStephan Stilgenbauer
Jun 27, 2006·Nature·Andrea L BredemeyerBarry P Sleckman
Nov 8, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Asher Chanan-KhanMyron S Czuczman
Nov 17, 2006·Leukemia·P DregerUNKNOWN Chronic Leukemia Working Party of the EBMT
Feb 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael R GreverJohn C Byrd
Aug 21, 2007·Best Practice & Research. Clinical Haematology·Thomas J Kipps
Aug 21, 2007·Best Practice & Research. Clinical Haematology·Thorsten ZenzStephan Stilgenbauer
Aug 21, 2007·Best Practice & Research. Clinical Haematology·Michael R GreverJohn C Byrd
Oct 31, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Belinda AustenTatjana Stankovic
Nov 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter HillmenJiri Mayer
Dec 22, 2007·Nature Reviews. Immunology·Ulf Klein, Riccardo Dalla-Favera

❮ Previous
Next ❯

Citations

Jan 13, 2012·Current Hematologic Malignancy Reports·Leopold SellnerThorsten Zenz
Aug 23, 2012·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·James R CerhanSusan L Slager
Apr 16, 2013·European Journal of Internal Medicine·Chiara Lobetti-BodoniEmanuele Zucca
Oct 9, 2014·International Journal of Hematology·Hany A LabibRasha L Etewa
Aug 3, 2013·Leukemia & Lymphoma·Tatjana Stankovic, Anna Skowronska
Jan 28, 2012·Leukemia & Lymphoma·Emeline de VironEric Van Den Neste
Oct 26, 2011·Leukemia & Lymphoma·Martina SeiffertThorsten Zenz
Oct 26, 2011·Leukemia & Lymphoma·Pauline Y HuangRichard I Christopherson
Nov 12, 2015·Biochimica Et Biophysica Acta·Nicole S NicholasAlan G Ramsay
Mar 26, 2011·Blood Reviews·Thorsten ZenzStephan Stilgenbauer
Apr 17, 2015·Journal of Hematology & Oncology·Marion LapierreVincent Cavaillès
May 18, 2013·The Journal of Molecular Diagnostics : JMD·Vera GrossmannAlexander Kohlmann
Sep 28, 2017·Oncotarget·Lucia NobiliAntonino Neri
Dec 7, 2011·Cancer Control : Journal of the Moffitt Cancer Center·Elizabeth M Sagatys, Ling Zhang
Apr 2, 2020·Cold Spring Harbor Perspectives in Medicine·Nicholas ChiorazziKanti R Rai
May 1, 2021·Cancers·Isabel González-Gascón-Y-MarínJosé-Ángel Hernández-Rivas

❮ Previous
Next ❯

Related Concepts

Related Feeds

B cells: Gene Expression

B lymphocytes are white blood cells that play a role in the adaptive immune system by secreting antibodies. Here is the latest research on gene expression in B cells.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Ataxia telangiectasia

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.